%0 Journal Article
%T Enhanced antitumoral efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumors
%A Rong Fan
%A Cheng Wang
%A Yang Wang
%A Ping Ren
%A Pingping Gan
%A Hui Ji
%A Zian Xia
%A Suiyu Hu
%A Qiongyao Zeng
%A Wei Huang
%A Yebin Jiang
%A Xi Huang
%J Journal of Translational Medicine
%D 2012
%I BioMed Central
%R 10.1186/1479-5876-10-101
%X In the present study, intra-dermal murine models of melanoma (B16) and colorectal carcinoma (CT26) were treated with E1B55kD deleted oncolytic adenovirus Adel55 or Adel55 incorporated with cHSF1, HSF1i, HSP70, or HSP90 by intra-tumoral injection. Tumors were surgically excised 72£¿h post injection and animals were analyzed for tumor resistance and survival rate.Approximately 95% of animals in the Adel55-cHSF1 treated group showed sustained resistance upon re-challenge with autologous tumor cells, but not in PBS, Adel55, or Adel55-HSF1i treated groups. Only 50¨C65% animals in the Adel55-HSP70 and Adel55-HSP90 treated group showed tumor resistance. Tumor resistance was associated with development of tumor type specific cellular immune responses. Adel55-cHSF1 treatment also showed higher efficacy in diminishing progression of the secondary tumor focus than Adel55-HSP70 or Adel55-HSP90 treatment.Besides by increasing its burst in tumor cells, cHSF1 could also augment the potential of E1B55kD deleted oncolytic adenovirus by increasing the tumor-specific immune response, which is beneficial to prevent tumor recurrence. cHSF1 is a better gene for neoadjuvant immunotherapy than other heat shock protein genes.
%K HSF1
%K Cancer immunotherapy
%K Oncolytic adenovirus
%U http://www.translational-medicine.com/content/10/1/101/abstract